Earnings
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
CEO says firm’s “three clear imperatives” to drive cash and “total shareholder return” comprise its “three S” plan. Perrigo’s net sales for the quarter down 1.6% to $1.14bn and for the year down 6.1% to $4.37bn.
Full-year revenues up 14% to $732m and Q4 up 5% to $186m. Communications VP Dan Dischner says results came from “resilience of our portfolio, driven by contributions from key products such as Primatene Mist and the integration of Baqsimi into our expanding diabetes franchise.”
Analysts hold back on predicting new heights for B+L until full split from parent firm. It reported Q4 revenue up 9% to $1.28bn and full-year revenue up 16% to $4.79bn.
The Swedish firm is plotting the path towards launching its ColdZyme virus-blocking spray in China and Japan, while efforts are also underway to find a partner for the North American market.
Energy, immunity and women's health supplements were in particular demand in 2024, according to French self-care industry association NèreS.
As Norway's Orkla Health searches for a new CEO, the business looks well-placed for future growth after a 15% uplift in sales in 2024.
Navamedic is seeing good early sales for OTC ED treatment Eroxon in multiple Nordic markets after investing in a marketing push which includes a Mission Impossible-inspired commercial.
PCH announces 2.7 % reported growth to $290.3m in revenues for its latest quarter. Fleet line extensions don’t the brand against fiber product lines such as Metamucil and Benefiber. Licenses all markets for Hydralyte outside US. Two more Clear Eyes suppliers to be added as current pair repair their processes.
UK-based Alliance Pharma reported a single-digit drop in Consumer Healthcare turnover ahead of a shareholder vote on the company's future ownership.
Industry’s results from October-December period start on 22 January with Procter & Gamble reporting its fiscal year 2025 second-quarter numbers and Abbott with its 2024 full-year and fourth-quarter information.
Major Europe-based consumer health players Haleon, Bayer and Reckitt feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q4 2024 results over the coming weeks.
PharmaSGP has added an additional €5m to the top-end of its sales guidance after recording a double-digit gain Italy and outpacing the growth of the OTC market in Germany.
A slowdown in China and the US, along with signs of a weaker cough & cold season in the latter, has led Bayer Consumer Health to lower its full-year sales guidance.
Finland is the latest market launch for OTC erectile dysfunction treatment Eroxon. High demand for the product in other countries, such as Norway, helped drive up Navamedic's consumer health sales in the first nine months of 2024.
“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.